Authors

Hypertension: A Silent Killer Requiring Novel Therapies

Hypertension is widespread and linked to serious health risks, but new treatments for resistant cases target new mechanisms of action.

Not A Laughing Matter: Emerging Nitrous Oxide Regulatory Oversight

Laughing gas misuse is surging as nitrous oxide drug abuse spreads online

Flushing the Old Away: Transitioning From Heparin to Saline for Implanted Port Maintenance

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

Afamitresgene autoleucel: The First T-Cell Receptor Therapy on the Market

Second-line and later treatment options for synovial sarcoma are limited. Afamitresgene autoleucel is the first FDA-approved T-cell receptor therapy, demonstrating long-lasting responses and tolerable adverse effects in pretreated patients.

From Quick Wins to Long-Term Infrastructure: A Pharmacist's Roadmap for Antithrombotic Stewardship

Darren Triller, PharmD, walks through the relative ease and impact of each of the 5 ADAPT priority areas, makes the case for dashboard-driven population health management.

A Student Pharmacist’s Guide to HIV Medications

Pharmacy students must have a comprehensive understanding of antiretrovirals to ensure efficiency and optimization of patients’ medical treatment.

How AON Built an Outpatient BiTE Therapy Program for Multiple Myeloma

In an interview with Pharmacy Times, Nicole McMullin, regional clinical pharmacist at American Oncology Network, discussed AON’s development of an all-outpatient approach to step-up dosing for bispecific T-cell engager therapy in multiple myeloma.

OTC Naloxone Expands Access, but Cost and Distribution Gaps Still Limit Overdose Prevention

In an interview with Pharmacy Times, Alison Newman, MPH, program operations specialist with the Center for Community-Engaged Drug Education, Epidemiology & Research at the Addictions, Drug & Alcohol Institute at the University of Washington, discusses the significance of OTC naloxone availability and the barriers that remain despite the introduction of additional products.

From the Infusion Chair to the System Level: What Nearly Losing My Life Taught Me About Site-of-Care Decisions

Subcutaneous Olanzapine in Schizophrenia: Expanding the Utility of a Proven Therapy

TV-44749 is a subcutaneous long-acting injectable form of olanzapine that is effective in schizophrenia while avoiding risks seen with the intramuscular formulation.

Addressing Burnout in Pharmacy Residency: A Comprehensive Approach to Enhancing Well-Being

Initiatives aim to reduce residents' high rates of depression and increase self-care skills.

Insights From HOPA 2025: Pharmacists Discuss CAR-T Safety at a Comprehensive Cancer Center

Amir Ali, PharmD, BCOP, and Allison Hsieh, PharmD share insights from their presentation about cytokine release syndrome, ICANS, and CAR T-cell therapy.

Oral Semaglutide Approved to Reduce the Risk of Cardiovascular Events

The FDA approved oral semaglutide to reduce the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes (T2D).

Apixaban vs Rivaroxaban: A Clearer Choice for VTE?

Although evidence supports safety of apixaban and rivaroxaban relative to warfarin, researchers had not directly compared their bleeding risk until last year.

ADA 2026: The Diabetes Education Gap Clinicians Can't Afford to Ignore

Pharmacy Times speaks with Joyce Lee, PharmD, APh, FCCP, BCPS, BCACP, CDCES, to breakdown the diabetes education gap that clinicians can't afford to ignore.

Emerging Targeted Therapies in Breast Cancer: Expanding HER2-Low and TROP-2 Breakthroughs Require Pharmacist Knowledge and Vigilance

ADCs are reshaping metastatic breast cancer and pharmacists' roles in treatment management.

Administration of Tivozanib via Gastrostomy Tube: A Pharmacokinetic Analysis

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

Opinion: The Pseudoscience of Personalized Compounding Prioritizes Convenience and Cost Over Science and Safety

Mass-produced compounded GLP-1 drugs bypass FDA safeguards, raising sterility, quality, and supply-chain risks—putting patients at risk despite ending shortages.

FDA Approves Furosemide Autoinjector for Treatment of Edema in CKD or Heart Failure

The autoinjector provides an accessible, at-home option for patients with chronic kidney disease (CKD) or heart failure who need treatment for fluid buildup.

John Green: "Tuberculosis Anywhere Is a Threat to People Everywhere"

Tuberculosis is a long-standing global health issue that requires continued public health vigilance to prevent a resurgence of this preventable and curable disease.

Supporting Access to Precision Medicine in Community Care Settings

Precision medicine transforms cancer care, enhancing patient outcomes through targeted therapies, yet faces challenges in community access and biomarker testing.

Paradoxical Hypotension After Inadvertent Intravenous Administration of Epinephrine

Raising awareness of the potentially fatal cardiovascular complications of epinephrine toxicity.

AI and Drug Information: Where OpenEvidence Stands Out—and Where Pharmacists Still Win

Like other HCPs, pharmacists use AI-driven tools to support the delivery of pharmacy-related services.

An Overview of Vitamins and Supplements in Multiple Sclerosis

By examining the evidence, pharmacists can gain insights into whether these supplements could be integrated into MS treatment regimens to improve patient outcomes.

What Real-World Data Show About Moving Patients From Humira to Biosimilars

Data show adalimumab biosimilars can replace brand-name treatment with minimal gaps, high persistence, and sharply lower drug costs for patients and plans.

The Next Phase of Vertical Integration: Wholesalers Follow the PBM Playbook

Combating the Post-Pandemic Pharmacy Workforce Shortage

The pharmaceutical industry is facing a critical talent shortage caused by fewer students entering the field, burnout and a lack of stability. We offer ways to combat the shortage.

Expert Discusses Logistical Considerations and Future Research Needs for Radiopharmaceuticals

Thor Halfdanarson, MD, outlines real-world challenges in radiopharmaceutical production and delivery and highlights key questions for upcoming trials, including alpha vs beta emitters and long-term toxicity.